Willem Lybaert

1.7k total citations
32 papers, 389 citations indexed

About

Willem Lybaert is a scholar working on Oncology, Epidemiology and Cancer Research. According to data from OpenAlex, Willem Lybaert has authored 32 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 11 papers in Epidemiology and 8 papers in Cancer Research. Recurrent topics in Willem Lybaert's work include Neuroendocrine Tumor Research Advances (10 papers), Neuroblastoma Research and Treatments (5 papers) and Lung Cancer Research Studies (5 papers). Willem Lybaert is often cited by papers focused on Neuroendocrine Tumor Research Advances (10 papers), Neuroblastoma Research and Treatments (5 papers) and Lung Cancer Research Studies (5 papers). Willem Lybaert collaborates with scholars based in Belgium, United States and Spain. Willem Lybaert's co-authors include Hans Wildiers, Nicolas Janus, Lionel Duck, Vincent Launay‐Vacher, Joseph Kerger, J-L. Canon, Joëlle Nortier, Wim Wynendaele, J-P. Machiels and Marc Peeters and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Willem Lybaert

25 papers receiving 376 citations

Peers

Countries citing papers authored by Willem Lybaert

Since Specialization

Citations

This map shows the geographic impact of Willem Lybaert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willem Lybaert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willem Lybaert more than expected).

Fields of papers citing papers by Willem Lybaert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willem Lybaert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willem Lybaert. The network helps show where Willem Lybaert may publish in the future.

Co-authorship network of co-authors of Willem Lybaert

This figure shows the co-authorship network connecting the top 25 collaborators of Willem Lybaert. A scholar is included among the top collaborators of Willem Lybaert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willem Lybaert. Willem Lybaert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pre- and Rehabilitation of Swallowing in Head and Neck Cancer Patients 2025 ·Current Otorhinolaryngology Reports ·(unknown), Leen Van den Steen, (unknown), (unknown), (unknown), Callum Faris, Willem Lybaert, Daan Nevens, Marika Rasschaert, (unknown), Gauthier Desuter, Gwen Van Nuffelen	0
2	Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol 2025 ·BMC Surgery ·(unknown), (unknown), Wim Ceelen, (unknown), (unknown), (unknown), Nele Vandenbussche, Kathleen Claes, (unknown), (unknown), (unknown), Willem Lybaert, (unknown), (unknown), (unknown), (unknown), Christophe Beyls, Mark P.S. Sie, Frederik Berrevoet	0
3	Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET/CT 2025 ·PubMed ·(unknown), (unknown), Karolien Goffin, (unknown), (unknown), Annouschka Laenen, Elin Pauwels, Willem Lybaert, Eric Van Cutsem, Guy Bormans, Timon Vandamme, Frederik Cleeren, Jeroen Dekervel, Karen Geboes, Sigrid Stroobants, Chris Verslype, Christophe M. Deroose	0
4	Clinical impact of using [ ¹⁸ F ] AlF ‐ NOTA ‐octreotide PET / CT instead of [ ⁶⁸ Ga ]Ga‐ DOTA ‐ SSA PET / CT : Secondary endpoint analysis of a multicenter, prospective trial 2024 ·Journal of Neuroendocrinology ·(unknown), Elin Pauwels, Timon Vandamme, (unknown), Willem Lybaert, Jeroen Dekervel, (unknown), Joris Jaekers, Frederik Cleeren, Johannes Hofland, Adrienne H. Brouwers, Michel Koole, Guy Bormans, Eric Van Cutsem, Karen Geboes, Annouschka Laenen, Chris Verslype, Sigrid Stroobants, Christophe M. Deroose	4
5	NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer 2023 ·Clinical Cancer Research ·(unknown), Greetje Vanhoutte, Willem Lybaert, Wim Demey, Jochen Decaestecker, (unknown), (unknown), Karen Zwaenepoel, Patrick Pauwels, Erik Fransén, Ken Op de Beeck, Guy Van Camp, Christian Rolfo, Marc Peeters	12
6	181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative 2023 ·Annals of Oncology ·Philippe Aftimos, Kevin Punie, Lore Decoster, Cédric van Marcke, Aline Hébrant, Gordana Raicevic, Els Van Valckenborgh, Brigitte Maes, (unknown), Joëlle Collignon, (unknown), (unknown), Wim Demey, Sabine Tejpar, Marc Peeters, J-L. Canon, Willem Lybaert, Jeroen Mebis, Sylvie Rottey, Jacques De Grève	0
7	High Protein Oral Nutritional Supplements Enable the Majority of Cancer Patients to Meet Protein Intake Recommendations during Systemic Anti-Cancer Treatment: A Randomised Controlled Parallel-Group Study 2023 ·Nutrients ·Anne‐Marie C. Dingemans, Nico van Walree, Franz M.N.H. Schramel, (unknown), (unknown), Willem Lybaert, M. Veldhorst, (unknown), Stein Kaasa	9
8	The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective 2023 ·Current Treatment Options in Oncology ·(unknown), (unknown), (unknown), Willem Lybaert, Marc Peeters, Guy Van Camp, Ken Op de Beeck, Timon Vandamme	5
9	Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study 2021 ·Clinical Therapeutics ·Lionel Duck, (unknown), Lionel D’Hondt, (unknown), Koen Hendrickx, (unknown), (unknown), Dominique Lossignol, (unknown), Willem Lybaert, (unknown), (unknown), (unknown), Karen Geboes	2
10	Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key 2021 ·Acta Clinica Belgica ·(unknown), Vibeke Krüse, Willem Lybaert	0
11	468P PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC) 2020 ·Annals of Oncology ·Katrien Janssens, Erik Fransén, Christian Rolfo, Willem Lybaert, Wim Demey, Jochen Decaestecker, Koen Hendrickx, (unknown), Ken Op de Beeck, Guy Van Camp, Marc Peeters	2
12	Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer 2018 ·ESMO Open ·Christian Rolfo, Paolo Manca, Roberto Salgado, Peter A. van Dam, Amélie Dendooven, (unknown), Annemie Rutten, Willem Lybaert, Joanna Vermeij, Thomas Gevaert, Christine Weyn, (unknown), (unknown), Steven Van Laere, Marc Peeters, Patrick Pauwels, (unknown)	63
13	Impact of NET MDT on overall survival within NETwerk, a collaborative ENETS Center of Excellence. 2018 ·Journal of Clinical Oncology ·Timon Vandamme, (unknown), (unknown), Pascale Abrams, Ann Driessen, Bart Op de Beeck, Wim Demey, (unknown), (unknown), Geert Roeyen, Willem Lybaert, Marc Peeters	0
14	Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. 2016 ·PubMed ·Bert van den Heuvel, Marc Peeters, Alain Hendlisz, Marc Van den Eynde, (unknown), (unknown), Karen Geboes, Marc De Man, Koen Hendrickx, Thierry Delaunoit, Els Monsaert, (unknown), Jean‐Luc Van Laethem, Willem Lybaert, Stéphane Holbrechts, Christian Rolfo	3
15	The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma 2014 ·Case Reports in Oncology ·Willem Lybaert	0
16	Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel®: A Case Report 2014 ·Case Reports in Oncology ·Willem Lybaert, (unknown), (unknown)	1
17	Cancer and renal insufficiency results of the BIRMA study 2010 ·British Journal of Cancer ·Nicolas Janus, Vincent Launay‐Vacher, (unknown), J-P. Machiels, Lionel Duck, Joseph Kerger, Wim Wynendaele, J-L. Canon, Willem Lybaert, Joëlle Nortier, (unknown), Hans Wildiers	133
18	Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) +/- trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data 2006 ·Breast Cancer Research and Treatment ·Willem Lybaert, Hans Wildiers, Patrick Neven, Paul Clement, Frédéric Amant, (unknown), Ann Smeets, Erik Van Limbergen, Caroline Weltens, (unknown), Guy Debrock, Robert Paridaens	9
19	Neoadjuvant capecitabine (X), docetaxel (T)±trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data from a multicentre phase II study 2006 ·European Journal of Cancer Supplements ·Willem Lybaert, Hans Wildiers, Patrick Neven, Paul Clement, (unknown), Caroline Weltens, (unknown), Chantal Van Ongeval, (unknown), Robert Paridaens	4
20	Neoadjuvant capecitabine (X) plus clocetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data 2005 ·European Journal of Cancer Supplements ·Willem Lybaert, Hans Wildiers, Patrick Neven, (unknown), Caroline Weltens, (unknown), Chantal Van Ongeval, (unknown), Robert Paridaens	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact